To view enhanced digital features for this article go to https://doi.org/10.6084/m9.figshare.7467554.
Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection among persons who inject drugs (PWID) is a major public health concern. There are limited data in clinical trials on the use of direct-acting antiviral (DAA) therapy for treatment of HCV in co-infected PWID. It is critical for these patients to gain access to treatment in order to decrease progression of liver disease and decrease transmission of both HIV and HCV. Additional harm reduction interventions, including needle and syringe programs and opioid substitution treatment, should be made available to this vulnerable population. Despite the importance of DAA treatment, the cost of DAA therapy and access to medical care is still a barrier to appropriate therapy. The purpose of this review is to present available data on the use of DAAs in co-infected PWID, review guideline recommendations for treatment and retreatment of HCV in co-infected PWID, provide cost considerations for DAA therapy, and provide recommendations about caring for patients who continue to inject drugs.
EASL. EASL Recommendations on Treatment of Hepatitis C. 2018. http://www.easl.eu/medias/cpg/2018/EASL%20Recommendations%20on%20Treatment%20of%20Hepatitis%20C%202018/English-report.pdf. Accessed 19 Jul 2018.
AASLD-IDSA. Key populations: identification and management of HCV in people who inject drugs. 2018. https://www.hcvguidelines.org/unique-populations/pwid. Accessed 19 Jul 2018.
Rockstroh JK, Lacombe K, Viani RM, et al. Efficacy and safety of glecaprevir/pibrentasvir in patients coinfected with hepatitis C virus and human immunodeficiency virus type 1: the EXPEDITION-2 study. Clin Infect Dis. 2018;67:1–8. CrossRef
Bentley TS, Phillips SJ, Hanson SG. 2017 US organ and tissue transplant cost estimates and discussion. Milliman Research Report. 2017. http://us.milliman.com/uploadedFiles/insight/2017/2017-Transplant-Report.pdf. Accessed 7 Jun 2018.
Gilead Sciences. Gilead subsidiary to launch authorized generics of Epclusa (sofosbuvir/velpatasvir) and Harvoni (ledipasvir/sofosbuvir) for the treatment of chronic hepatitis C. 2018. Available at https://www.gilead.com/news-and-press/press-room/press-releases/2018/9/gileadsubsidiary-to-launchauthorized-generics-of-epclusa-sofosbuvirvelpatasvir-and-harvoniledipasvirsofosbuvir-for-the-treatment-of-chronic.. Accessed 28 Dec 2018.
Dore GJ, Grebely J, Altice F, Litwin AH, Dalgard O, Gane E, et al. Hepatitis C virus reinfection and injecting risk behavior following elbasvir/grazoprevir treatment in participants on opiate agonist therapy: C-EDGE CO-STAR part B. In: AASLD Annual Meeting, October 22nd 2017. Washington, DC. 2017.
U.S. Department of Health and Human Services. HIV and people who use illicit drugs. Available at https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv/22/hiv-and-people-who-use-illicit-drugs. 2012. Accessed 28 Dec 2018.
Epclusa ® [package insert]. Foster City, CA: Gilead Sciences, Inc. 2016.
Harvoni ® [package insert]. Foster City, CA: Gilead Sciences, Inc. 2017.
Mavyret ® [package insert]. North Chicago, IL: AbbVie Inc. 2017.
Olysio ® [package insert]. Titusville, NJ: Janssen Therapeutics. 2013.
Solvadi ® [package insert]. Foster City, CA: Gilead Sciences, Inc. 2017.
Zepatier ® [package insert]. Whitehouse Station, NJ: Merck & Co., Inc. 2018.
Technivie ® [package insert]. North Chicago, IL: AbbVie Inc. 2017.
Viekira XR ® [package insert]. North Chicago, IL: AbbVie Inc. 2017.
Daklinza ® [package insert]. Princeton, NJ: Bristol-Myers Squibb Company. 2017.
Weltman M, Fragomeli V. Addressing viral hepatitis in the opiate substitution setting: an integrated nursing model of care. J Gastroentrol Hepatol. 2015;30(Suppl. 2):6–11.
- Public Health Considerations among People who Inject Drugs with HIV/HCV Co-Infection: A Review
Rachel M. Murdock
Marisa B. Brizzi
Melissa E. Badowski
- Springer Healthcare
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II